Takeda’s U.S. Approval For Alogliptin Boosts Prospects Of Contrave And TAK-875
This article was originally published in PharmAsia News
Executive Summary
With a reenergized metabolic infrastructure, Takeda can otherwise “digest” its acquisition of Nycomed, because no transformative deals are in near sight.
You may also be interested in...
Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013
Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?